Tevimbra may be prescribed in general hospitals in KOR
By Eo, Yun-Ho | translator Kang, Shin-Kook
24.09.02 05:52:07
가나다라
0
Passed the DCs of medical institutions such as SMC and SNUH
Has been set reimbursement standards at the CDDC meeting on the 28th…whether it will be listed for reimbursement gains attention
According to industry sources, BeiGene Korea's PD-1 inhibitor Tevimbra (tiselizumab) has passed the drug committees (DCs) of tertiary hospitals, including Samsung Medical Center and Seoul National University Hospital.
In addition, the company succeeded in reapplying for Tevimbra’s reimbursement to the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee, raising the possibility of its insurance reimbursement.
Tevimbra had previously received the ‘reimbursement standards not set' decision by the CDDC in March. The company had resubmitted its reimburs
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)